MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPE21 November 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosis26 October 2023
Watch the recording of the EHA 2023 highlights webinarAL amyloidosis, MPE, Myeloma, Videos10 July 2023
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, Myeloma14 June 2023
EHA 2023 highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, Myeloma, Videos14 June 2023
ASH 2022 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, Myeloma, Videos12 December 2022
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidence21 June 2021
